Literature DB >> 11892075

Recombinant allergens/allergen standardization.

H Løwenstein1, J N Larsen.   

Abstract

Recombinant allergens are genetically engineered isoforms representing allergen molecules from allergen extracts. Immunologic responses of allergic patients toward allergen extracts define the major allergens. For the average allergic patient, the diagnostic sensitivity and treatment efficacy correlate with the concentration of major allergen. Standardization of allergen products (extracts or genetically engineered allergens) can therefore advantageously be performed using a selected recombinant major allergen as a standard. The standardization will furthermore require reagents for which both monospecific, monoclonal, or preferably, recombinant antibodies can be used. Due to differences in the allergenic activity of individual isoallergens and the naturally occurring mixture of isoallergens found in an allergen extract, and due to additional contribution to the allergenic activity from other molecules in the extract, a biologic potency assessment must always be performed as a supplement. This is also the case for a genetically engineered allergen product.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11892075     DOI: 10.1007/s11882-001-0036-0

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  34 in total

1.  The significance of isoallergenic variations in present and future specific immunotherapy.

Authors:  H Løwenstein; S H Sparholt; S S Klysner; H Ipsen; J N Larsen
Journal:  Int Arch Allergy Immunol       Date:  1995 May-Jun       Impact factor: 2.749

2.  The international collaborative study on the first international standard of birch (Betula verrucosa)-pollen extract.

Authors:  F C Arntzen; T W Wilhelmsen; H Løwenstein; B Gjesing; H J Maasch; R Strömberg; R Einarsson; A Backman; S Mäkinen-Kiljunen; A Ford
Journal:  J Allergy Clin Immunol       Date:  1989-01       Impact factor: 10.793

3.  Radioimmunosorbent assay of allergens.

Authors:  M Ceska; R Eriksson; J M Varga
Journal:  J Allergy Clin Immunol       Date:  1972-01       Impact factor: 10.793

4.  Immunotherapy of hay fever with ragweed antigen E: comparisons with whole pollen extract and placebos.

Authors:  P S Norman; W L Winkenwerder; L M Lichtenstein
Journal:  J Allergy       Date:  1968-08

5.  A comparative study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hay fever.

Authors:  T E Van Metre; N F Adkinson; F J Amodio; L M Lichtenstein; M R Mardiney; P S Norman; G L Rosenberg; A K Sobotka; M D Valentine
Journal:  J Allergy Clin Immunol       Date:  1980-12       Impact factor: 10.793

6.  Immunotherapy in bee sting hypersensitivity. Bee venom versus wholebody extract.

Authors:  U Müller; U Thurnheer; R Patrizzi; J Spiess; R Hoigné
Journal:  Allergy       Date:  1979-12       Impact factor: 13.146

7.  Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of bronchial responses to cat allergen and histamine.

Authors:  W W Taylor; J L Ohman; F C Lowell
Journal:  J Allergy Clin Immunol       Date:  1978-05       Impact factor: 10.793

8.  Production and testing of an international reference standard of short ragweed pollen extract.

Authors:  R M Helm; M B Gauerke; H Baer; H Løwenstein; A Ford; D A Levy; P S Norman; J W Yunginger
Journal:  J Allergy Clin Immunol       Date:  1984-06       Impact factor: 10.793

9.  Prospective study on immunologic changes induced by two different Dermatophagoides pteronyssinus extracts prepared from whole mite culture and mite bodies.

Authors:  U Wahn; C Schweter; P Lind; H Løwenstein
Journal:  J Allergy Clin Immunol       Date:  1988-09       Impact factor: 10.793

10.  Dose response of IgE and IgG antibodies during ragweed immunotherapy.

Authors:  P S Creticos; T E Van Metre; M R Mardiney; G L Rosenberg; P S Norman; N F Adkinson
Journal:  J Allergy Clin Immunol       Date:  1984-01       Impact factor: 10.793

View more
  2 in total

1.  The Major Peanut Allergen Ara h 2 Produced in Nicotiana benthamiana Contains Hydroxyprolines and Is a Viable Alternative to the E. Coli Product in Allergy Diagnosis.

Authors:  Öykü Üzülmez; Tanja Kalic; Vanessa Mayr; Nina Lengger; Angelika Tscheppe; Christian Radauer; Christine Hafner; Wolfgang Hemmer; Heimo Breiteneder
Journal:  Front Plant Sci       Date:  2021-10-04       Impact factor: 6.627

Review 2.  Global View on Ant Venom Allergy: from Allergenic Components to Clinical Management.

Authors:  Troy Wanandy; Emily Mulcahy; Wun Yee Lau; Simon G A Brown; Michael D Wiese
Journal:  Clin Rev Allergy Immunol       Date:  2021-06-01       Impact factor: 8.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.